Literature DB >> 19403062

CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients.

Yongsheng Yu1, Hao Wu, Zhenghao Tang, Guoqing Zang.   

Abstract

To determine whether RNA interference (RNAi) could block cytotoxic T-lymphocyte antigen 4 (CTLA4) in human lymphocytes in vitro and promote IFN-gamma and IL-2 secretions, three small interfering RNAs (siRNAs) were selected based on target specificity sequences of human CTLA4 and transfected into human lymphocytes of chronic HBV patients. As a result, the expression of human CTLA4 mRNA was efficiently suppressed by all the three siRNAs. Compared with negative control (siRNA-co), siRNA-1 inhibited the expression of CTLA4 most efficiently and was used in the further study. The expressions of IFN-gamma and IL-2 were upregulated and the level of IL-4 was almost unchanged in lymphocytes transfected with siRNA-1 compared with the blank control. These results indicated that siRNA-1 led to IFN-gamma and IL-2 secretions, which is a main response of Th1/Th2. In a conclusion, RNAi significantly suppressed the expression of human CTLA4 mRNA in human lymphocytes in vitro, and could induce Th1/Th2 response. It could be a new therapeutic strategy for chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403062      PMCID: PMC4002649          DOI: 10.1038/cmi.2009.17

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  8 in total

Review 1.  Restoring homeostasis of CD4⁺ T cells in hepatitis-B-virus-related liver fibrosis.

Authors:  Li-Sha Cheng; Yun Liu; Wei Jiang
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.

Authors:  Guoping Peng; Benyan Luo; Jie Li; Dongjiu Zhao; Wei Wu; Feng Chen; Zhi Chen
Journal:  J Clin Immunol       Date:  2010-12-01       Impact factor: 8.317

Review 3.  T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.

Authors:  B Ye; X Liu; X Li; H Kong; L Tian; Y Chen
Journal:  Cell Death Dis       Date:  2015-03-19       Impact factor: 8.469

Review 4.  Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.

Authors:  Hyosun Cho; Hyojeung Kang; Hwan Hee Lee; Chang Wook Kim
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

Review 5.  CTLA‑4 interferes with the HBV‑specific T cell immune response (Review).

Authors:  Hui Cao; Ruiwen Zhang; Wei Zhang
Journal:  Int J Mol Med       Date:  2018-05-17       Impact factor: 4.101

Review 6.  Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy.

Authors:  Mouldy Sioud
Journal:  Cancers (Basel)       Date:  2019-02-03       Impact factor: 6.639

Review 7.  Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?

Authors:  Ganesh Selvaraj Duraisamy; Dattatry Bhosale; Ivana Lipenská; Ivana Huvarova; Daniel Růžek; Marc P Windisch; Andrew D Miller
Journal:  Viruses       Date:  2020-09-07       Impact factor: 5.048

8.  Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative.

Authors:  Dawei Cui; Daixi Jiang; Cuilin Yan; Xia Liu; Yan Lv; Jue Xie; Yu Chen
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.